Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P14854
UPID:
CX6B1_HUMAN
Alternative names:
Cytochrome c oxidase subunit VIb isoform 1
Alternative UPACC:
P14854; B2R5C9; Q6IBL4
Background:
Cytochrome c oxidase subunit 6B1, also known as Cytochrome c oxidase subunit VIb isoform 1, plays a pivotal role in the mitochondrial electron transport chain. It is a crucial component of cytochrome c oxidase, the enzyme responsible for the reduction of oxygen to water, facilitating oxidative phosphorylation. This process is vital for the production of ATP, the energy currency of the cell.
Therapeutic significance:
The protein is linked to Mitochondrial complex IV deficiency, nuclear type 7, a disorder characterized by encephalomyopathy, muscle weakness, and neurodegeneration, among other symptoms. Understanding the role of Cytochrome c oxidase subunit 6B1 could open doors to potential therapeutic strategies for this mitochondrial disorder.